Copyright
©The Author(s) 2021.
World J Stem Cells. Dec 26, 2021; 13(12): 1826-1844
Published online Dec 26, 2021. doi: 10.4252/wjsc.v13.i12.1826
Published online Dec 26, 2021. doi: 10.4252/wjsc.v13.i12.1826
Table 1 Comparison between primary mesenchymal stem cells and mesenchymal stem cells derived from human pluripotent stem cells
Comparison | Primary MSCs | hPSC-MSCs | Ref. |
Cell number | Limited | Unlimited | [17,36] |
Proliferation | Slower | Faster | [36,39,42,43,48,57] |
Life span | Shorter | Longer | [17] |
Variation | Higher | Lower | [119] |
Differentiation potential | Higher | Lower, esp. adipogenesis | [31,43,47,48] |
Immunosuppression | Higher | Lower | [38,46] |
Pluripotent genes | Lower | Higher | [45] |
Mesenchymal genes | Higher | Lower | [45] |
VCAM1 | Higher | Lower | [44] |
HLA-II | Higher | Lower | [46] |
- Citation: Liu TM. Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World J Stem Cells 2021; 13(12): 1826-1844
- URL: https://www.wjgnet.com/1948-0210/full/v13/i12/1826.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i12.1826